Nicolas Ketterer

Lausanne, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.

Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.

Journal: Leukemia
Published: April 03, 2024

Angioimmunoblastic T-cell lymphoma and Kaposi sarcoma: A fortuitous collision?

Angioimmunoblastic T-cell lymphoma and Kaposi sarcoma: A fortuitous collision?

Journal: Histopathology
Published: August 26, 2023

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.

Journal: Blood advances
Published: September 07, 2022

ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study.

ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study.

Journal: Haematologica
Published: May 21, 2022

Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.

Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.

Journal: Swiss medical weekly
Published: April 04, 2019

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 20, 2018

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.

Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 30, 2016

Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).

Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).

Journal: Hematological oncology
Published: May 29, 2016

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.

Journal: Leukemia & lymphoma
Published: April 28, 2016

Can Low Dose Radiation Therapy (2 × 2 Gy) be Used in Primary Bilateral Conjunctival Follicular Lymphoma?

Can Low Dose Radiation Therapy (2 × 2 Gy) be Used in Primary Bilateral Conjunctival Follicular Lymphoma?

Journal: Klinische Monatsblatter fur Augenheilkunde
Published: April 27, 2016

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.

Journal: Hematological oncology
Published: February 01, 2016

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 23, 2015
Showing 1-12 of 27

Last Updated: 09/26/2026